| Journal of Clinical Gynecology and Obstetrics, ISSN 1927-1271 print, 1927-128X online, Open Access |
| Article copyright, the authors; Journal compilation copyright, J Clin Gynecol Obstet and Elmer Press Inc |
| Journal website https://jcgo.elmerpub.com |
Short Communication
Volume 14, Number 3, October 2025, pages 91-95
Intrapartum Terbutaline Use and Cesarean Delivery for Labor Dystocia
Tables
| No terbutaline (n = 683) | Received terbutaline (n = 161) | P-value | |
|---|---|---|---|
| All data presented as n (%) unless otherwise noted. aMedian (IQR). IOL: induction of labor; IQR: interquartile range; NRFHT: non-reassuring fetal heart tracing. | |||
| Agea | 28.2 (23.8 - 33.2) | 27.9 (22.6 - 32.5) | 0.24 |
| Body mass index (kg/m2)a | 32.7 (28.1 - 37.6) | 33.1 (29.2 - 39.0) | 0.09 |
| Nulliparous | 423 (61.9) | 112 (69.6) | 0.07 |
| Race | 0.59 | ||
| White | 138 (20.2) | 27 (16.8) | |
| Black | 488 (71.4) | 121 (75.2) | |
| Other | 57 (8.3) | 13 (8.1) | |
| Ethnicity | 0.48 | ||
| Non-Hispanic | 661 (96.8) | 154 (95.7) | |
| Hispanic | 22 (3.2) | 7 (4.3) | |
| Gestational or pre-gestational diabetes | 38 (5.5) | 12 (7.4) | 0.35 |
| Chronic hypertension | 53 (7.8) | 6 (3.7) | 0.07 |
| Pregnancy related hypertension | 228 (32.9) | 58 (35.8) | 0.48 |
| Indication for IOL | 0.65 | ||
| Post-dates | 105 (15.4) | 24 (14.9) | |
| Maternal indication | 190 (27.8) | 45 (28.0) | |
| Fetal indication | 306 (44.8) | 78 (48.4) | |
| Elective/other | 82 (12.0) | 14 (8.7) | |
| Gestational age at deliverya | 39.3 (38.1 - 40.6) | 39.4 (38.4 - 40.6) | 0.52 |
| Initial cervical dilationa | 1.0 (1.0 - 1.5) | 1.0 (0.5 - 1.5) | <0.01 |
| Initial Bishop score | 3 (2, 5) | 3 (2, 5) | 0.08 |
| No terbutaline (n = 683) | Received terbutaline (n = 161) | P-value | |
|---|---|---|---|
| All data presented as n (%) unless otherwise noted. aMedian (IQR). bP-value among doses 0.31. cTime from initiation of induction to delivery of the neonate regardless of ultimate mode of delivery. IQR: interquartile range; NRFHT: non-reassuring fetal heart tracing. | |||
| Cesarean delivery | 162 (24) | 82 (51) | < 0.001 |
| Cesarean for NRFHT | 29 (4.2) | 42 (26.1) | < 0.001 |
| Cesarean for labor dystocia | 133 (19.5) | 40 (24.8) | 0.13 |
| Number of doses of terbutaline | - | 1 dose: 21 (22.3) 2 doses: 13 (26.5) > 3 doses: 6 (33.3)b |
0.31 |
| Latent phase (h)a | 10.4 (7.2 - 15.1) | 11.8 (7.9 - 17.7) | 0.02 |
| Active phase (h)a | 2.3 (0.5 - 5.2) | 2.5 (0.0 - 5.9) | 0.66 |
| Second stage (h)a | 0.5 (0.2 - 1.3) | 0.6 (0.2 - 1.3) | 0.47 |
| Length of labor (h)a, c | 16.2 (10.8 - 23.2) | 18.3 (14.1 - 25.8) | < 0.01 |